ENXTPA:SANPharmaceuticals
The Bull Case For Sanofi (ENXTPA:SAN) Could Change Following Tzield Momentum And Autoimmune Push
In early January 2026, BrightInsight reported improved adherence and persistence from its Patient App for a key Sanofi–Regeneron biologic, while Sanofi also expanded its immunology footprint through a potential US$2.56 billion-plus autoimmune collaboration with Earendil Labs and advanced Tzield via US priority review in young children and European approval to delay type 1 diabetes progression.
These developments highlight how Sanofi is pairing digital tools with regulatory progress in...